Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Mesoblast Limited — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $89.36 (market cap $41.13B), while Mesoblast Limited trades at $14.3 (market cap $1.75B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 23.5× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 10,340,382). Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and Mesoblast Limited for 15 Days on average.
| IEF | MESO | |
|---|---|---|
Market Cap | $41.13B | $1.75B |
Volume | 10,340,382 | 239,027 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $20.96 |
52-Week Low | $88.92 | $13.19 |
Typical Hold Time | 108 Days | 15 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF trades at $89.335, up 0.25% with a bearish technical signal from moving averages. The fund shows neutral oscillator readings with RSI at 52.94. Recent dividend payments of $0.31-$0.33 provide income, while bond market volatility and rising Treasury yields create headwinds. Support is clustered around $89 with resistance at $90.
The outlook remains cautious amid persistent bond market pressure. While dividend income offers stability, the bearish technical trend and macroeconomic uncertainty suggest limited near-term upside. Key risks include continued yield increases and inflation concerns that could pressure bond prices further.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
